184 related articles for article (PubMed ID: 34638945)
1. A 4-Gene Signature of CDKN1, FDXR, SESN1 and PCNA Radiation Biomarkers for Prediction of Patient Radiosensitivity.
Howe O; White L; Cullen D; O'Brien G; Shields L; Bryant J; Noone E; Bradshaw S; Finn M; Dunne M; Shannon AM; Armstrong J; McClean B; Meade A; Badie C; Lyng FM
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638945
[TBL] [Abstract][Full Text] [Related]
2. Chromosomal radiosensitivity analyzed by FISH in lymphocytes of prostate cancer patients and healthy donors.
Schmitz S; Brzozowska K; Pinkawa M; Eble M; Kriehuber R
Radiat Res; 2013 Nov; 180(5):465-73. PubMed ID: 24083681
[TBL] [Abstract][Full Text] [Related]
3. The potential role of G2- but not of G0-radiosensitivity for predisposition of prostate cancer.
Borgmann K; Raabe A; Reuther S; Szymczak S; Schlomm T; Isbarn H; Gomolka M; Busjahn A; Bonin M; Ziegler A; Dikomey E
Radiother Oncol; 2010 Jul; 96(1):19-24. PubMed ID: 20452694
[TBL] [Abstract][Full Text] [Related]
4. Chromosomal in-vitro radiosensitivity of lymphocytes in radiotherapy patients and AT-homozygotes.
Dunst J; Neubauer S; Becker A; Gebhart E
Strahlenther Onkol; 1998 Oct; 174(10):510-6. PubMed ID: 9810318
[TBL] [Abstract][Full Text] [Related]
5. Androgen deprivation modulates gene expression profile along prostate cancer progression.
Volante M; Tota D; Giorcelli J; Bollito E; Napoli F; Vatrano S; Buttigliero C; Molinaro L; Gontero P; Porpiglia F; Tucci M; Papotti M; Berruti A; Rapa I
Hum Pathol; 2016 Oct; 56():81-8. PubMed ID: 27342909
[TBL] [Abstract][Full Text] [Related]
6. In vivo versus in vitro individual radiosensitivity analysed in healthy donors and in prostate cancer patients with and without severe side effects after radiotherapy.
Brzozowska K; Pinkawa M; Eble MJ; Müller WU; Wojcik A; Kriehuber R; Schmitz S
Int J Radiat Biol; 2012 May; 88(5):405-13. PubMed ID: 22348555
[TBL] [Abstract][Full Text] [Related]
7. Examining Radiation-Induced In Vivo and In Vitro Gene Expression Changes of the Peripheral Blood in Different Laboratories for Biodosimetry Purposes: First RENEB Gene Expression Study.
Abend M; Badie C; Quintens R; Kriehuber R; Manning G; Macaeva E; Njima M; Oskamp D; Strunz S; Moertl S; Doucha-Senf S; Dahlke S; Menzel J; Port M
Radiat Res; 2016 Feb; 185(2):109-23. PubMed ID: 26829612
[TBL] [Abstract][Full Text] [Related]
8. Cell death mechanisms associated with G2 radiosensitivity in patients with prostate cancer and benign prostatic hyperplasia.
Howe O; O'Malley K; Lavin M; Gardner RA; Seymour C; Lyng F; Mulvin D; Quinlan DM; Mothersill C
Radiat Res; 2005 Nov; 164(5):627-34. PubMed ID: 16238439
[TBL] [Abstract][Full Text] [Related]
9. Chromosomal radiosensitivity of triple negative breast cancer patients.
Francies FZ; Herd O; Cairns A; Nietz S; Murdoch M; Slabbert J; Claes KBM; Vral A; Baeyens A
Int J Radiat Biol; 2019 Nov; 95(11):1507-1516. PubMed ID: 31348739
[No Abstract] [Full Text] [Related]
10. Functional p53 increases prostate cancer cell survival after exposure to fractionated doses of ionizing radiation.
Scott SL; Earle JD; Gumerlock PH
Cancer Res; 2003 Nov; 63(21):7190-6. PubMed ID: 14612513
[TBL] [Abstract][Full Text] [Related]
11. Development and Validation of a Prostate Cancer Genomic Signature that Predicts Early ADT Treatment Response Following Radical Prostatectomy.
Karnes RJ; Sharma V; Choeurng V; Ashab HA; Erho N; Alshalalfa M; Trock B; Ross A; Yousefi K; Tsai H; Zhao SG; Tosoian JJ; Haddad Z; Takhar M; Chang SL; Spratt DE; Abdollah F; Jenkins RB; Klein EA; Nguyen PL; Dicker AP; Den RB; Davicioni E; Feng FY; Lotan TL; Schaeffer EM
Clin Cancer Res; 2018 Aug; 24(16):3908-3916. PubMed ID: 29760221
[No Abstract] [Full Text] [Related]
12. Impact of radiation dose on recurrence in high-risk prostate cancer patients.
Deek M; Lilleby W; Vaage V; Hole KH; DeWeese T; Stensvold A; Tran P; Seierstad T
Prostate; 2020 Nov; 80(15):1322-1327. PubMed ID: 33258482
[TBL] [Abstract][Full Text] [Related]
13. G2 checkpoint control and G2 chromosomal radiosensitivity in cancer survivors and their families.
Cadwell KK; Curwen GB; Tawn EJ; Winther JF; Boice JD
Mutagenesis; 2011 Mar; 26(2):291-4. PubMed ID: 21044988
[TBL] [Abstract][Full Text] [Related]
14. The need for androgen deprivation therapy in patients with intermediate-risk prostate cancer treated with dose-escalated external beam radiation therapy.
Dong Y; Ruth KJ; Churilla TM; Viterbo R; Sobczak ML; Smaldone MC; Chen DY; Uzzo RG; Hallman MH; Horwitz EM
Can J Urol; 2017 Feb; 24(1):8656-8662. PubMed ID: 28263132
[TBL] [Abstract][Full Text] [Related]
15. Initial results of a randomized phase III trial of high dose image guided radiation with or without androgen deprivation therapy for intermediate-risk prostate cancer.
Vargas CE; Alam NB; Terk M; Niska JR; Cesaretti J; Swartz D; Vashi A; Kasraeian A; West CS; Blasser M; Moore C
Cancer Treat Res Commun; 2019; 19():100119. PubMed ID: 30772671
[TBL] [Abstract][Full Text] [Related]
16. Acute Epithelial Toxicity Is Prognostic for Improved Prostate Cancer Response to Radiation Therapy: A Retrospective, Multicenter, Cohort Study.
Eade T; Choudhury A; Pollack A; Abramowitz M; Chinea FM; Guo L; Kennedy J; Louw S; Hruby G; Kneebone A; West C
Int J Radiat Oncol Biol Phys; 2018 Jul; 101(4):957-963. PubMed ID: 29976508
[TBL] [Abstract][Full Text] [Related]
17. G2-checkpoint abrogation in irradiated lymphocytes: A new cytogenetic approach to assess individual radiosensitivity and predisposition to cancer.
Terzoudi GI; Hatzi VI; Barszczewska K; Manola KN; Stavropoulou C; Angelakis P; Pantelias GE
Int J Oncol; 2009 Nov; 35(5):1223-30. PubMed ID: 19787278
[TBL] [Abstract][Full Text] [Related]
18. A standardized G2-assay for the prediction of individual radiosensitivity.
Pantelias GE; Terzoudi GI
Radiother Oncol; 2011 Oct; 101(1):28-34. PubMed ID: 22014898
[TBL] [Abstract][Full Text] [Related]
19. Identification and validation of single-sample breast cancer radiosensitivity gene expression predictors.
Sjöström M; Staaf J; Edén P; Wärnberg F; Bergh J; Malmström P; Fernö M; Niméus E; Fredriksson I
Breast Cancer Res; 2018 Jul; 20(1):64. PubMed ID: 29973242
[TBL] [Abstract][Full Text] [Related]
20. Dose-escalated radiotherapy for high-risk prostate cancer: outcomes in modern era with short-term androgen deprivation therapy.
Liauw SL; Stadler WM; Correa D; Weichselbaum RR; Jani AB
Int J Radiat Oncol Biol Phys; 2010 May; 77(1):125-30. PubMed ID: 19695789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
